Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Social Psychiatry and Psychiatric Epidemiology
Published in: Social Psychiatry and Psychiatric Epidemiology 1/2012

01-01-2012 | Original Paper

Adverse effects of antipsychotic drugs: survey of doctors’ versus patients’ perspective

Authors: Michela Nosè, Maria Angela Mazzi, Eleonora Esposito, Marco Bianchini, Paola Petrosemolo, Giovanni Ostuzzi, Michele Tansella, Corrado Barbui

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 1/2012

Login to get access

Abstract

Aims

Almost no data are available on whether patients and doctors have similar or dissimilar opinions on the presence and level of distress due to antipsychotic adverse effects. The aim of this survey is to compare doctors’ versus patients’ perspective on the presence and level of distress due to antipsychotic adverse effects in a sample of patients under the care of the South-Verona mental health services.

Methods

All patients exposed to antipsychotic drugs during a census period of 6 months were identified. For each included subject, socio-demographic, clinical and treatment data were extracted. Patients’ perspective on antipsychotic adverse effects was measured by means of the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS). The LUNSERS was similarly employed to measure doctors’ perspective on antipsychotic adverse effects.

Results

During the recruitment period, 243 patients taking antipsychotic drugs were enrolled. The correlation between the total LUNSERS score reported by patients and doctors was very low (correlation coefficient 0.22, 95% confidence interval 0.15–0.30). On average, patients perceived more adverse effects and with a significant higher distress than doctors. Multivariate analyses found no factors simultaneously associated with both patient and doctor ratings of adverse effects.

Conclusion

Our study suggests that doctors, researchers and health care providers should increasingly consider patient and doctor perspectives as two complementary dimensions that may provide different insights in the evaluation of antipsychotic drugs. Integrating different points of view may represent a way to develop a better therapeutic alliance that might decrease the likelihood of nonadherence.
Literature
1.
Amaddeo F, Tansella M (2009) Information systems for mental health. Epidemiol Psichiatr Soc 18(1):1–4PubMed
2.
Barbui C, Nosè M, Rambaldelli G, Bonetto C, Levi D, Patten S et al (2005) Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research. Int J Methods Psych Res 14:151–157CrossRef
3.
Barbui C, Nose M, Bindman J, Schene A, Becker T, Mazzi MA et al (2005) Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 25(6):521–526PubMedCrossRef
4.
Berkanovic E, Hurwicz ML, Lachenbruch PA (1995) Concordant and discrepant views of patients’ physical functioning. Arthritis Care Res 8(2):94–101PubMedCrossRef
5.
Bonetto C, Nose M, Barbui C (2006) Generating drug exposure data from computer-based medical records. Comput Methods Programs Biomed 83:120–124PubMedCrossRef
6.
Davidson L, Miller R, Flanagan E (2008) What’s in it for me? The utility of psychiatric treatments from the perspective of the person in recovery. Epidemiol Psichiatr Soc 17(3):177–181PubMed
7.
Day JC, Wood G, Dewey M, Bentall RP (1995) A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166(5):650–653PubMedCrossRef
8.
Day JC, Kinderman P, Bentall R (1998) A comparison of patients’ and prescribers’ beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 97(1):93–97PubMedCrossRef
9.
Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D et al (2005) Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 62(7):717–724PubMedCrossRef
10.
Evangelou E, Tsianos G, Ioannidis JP (2008) Doctors’ versus patients’ global assessments of treatment effectiveness: empirical survey of diverse treatments in clinical trials. BMJ 336(7656):1287–1290PubMedCrossRef
11.
Finn SE, Bailey JM, Schultz RT, Faber R (1990) Subjectiveutility ratings of neuroleptics in treating schizophrenia. Psychol Med 20(4):843–848PubMedCrossRef
12.
Fleiss JL (1981) Statistical methods for rates and proportions. New York, John Wiley & Sons
13.
Fonda SJ, Herzog AR (2001) Patterns and risk factors of change in somatic and mood symptoms among older adults. Ann Epidemiol 11(6):361–368PubMedCrossRef
14.
Gray R, Leese M, Bindman J, Becker T, Burti L, David A et al (2006) Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry 189:508–514PubMedCrossRef
15.
Hamer S, Haddad PM (2007) Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl 50:s64–s70PubMedCrossRef
16.
Huffman JC, Blais MA, Pirl WF (2004) A comparison of clinician and patient concerns about antipsychotic side effects: a pilot study. J Nerv Ment Dis 192(4):328–330PubMedCrossRef
17.
Kwoh CK, Ibrahim SA (2001) Rheumatology patient and physician concordance with respect to important health and symptom status outcomes. Arthritis Rheum 45(4):372–377PubMedCrossRef
18.
Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, Golks D, Naber D (2004) Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 19(7):415–422PubMedCrossRef
19.
Landis JR, Koch GG (1977) An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 33(2):363–374PubMedCrossRef
20.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–1223PubMedCrossRef
21.
Morrison P, Gaskill D, Meehan T, Lunney P, Lawrence G, Collings P (2000) The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Aust N Z J Ment Health Nurs 9(4):166–176PubMedCrossRef
22.
Naber D (2008) Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiol Psichiatr Soc 17(3):174–176PubMed
23.
Nose M (2008) Tolerability of antipsychotic drugs: does patient perspective deserve consideration? Epidemiol Psichiatr Soc 17(3):182–185PubMed
24.
Nose M, Barbui C (2008) A simple approach to manage dosages in drug-epidemiology research. Epidemiol Psichiatr Soc 17(3):186–187
25.
Nose M, Accordini S, Artioli P, Barale F, Barbui C, Beneduce R et al (2009) Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials 10:31PubMedCrossRef
26.
Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J (2009) Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107(1):22–29PubMedCrossRef
27.
Swift JK, Callahan JL (2009) The impact of client treatment preferences on outcome: a meta-analysis. J Clin Psychol 65(4):368–381PubMedCrossRef
28.
Tansella M, Burti L (2003) Integrating evaluative research and community-based mental health care in Verona, Italy. Br J Psychiatry 183:167–169PubMedCrossRef
29.
Tansella M, Amaddeo F, Burti L, Lasalvia A, Ruggeri M (2006) Evaluating a community-based mental health service focusing on severe mental illness. The Verona experience. Acta Psychiatr Scand Suppl 429:90–94PubMedCrossRef
30.
Zellner A (1962) An efficient method of estimating seemingly unrelated regressions and tests for aggregation bias. J Am Stat Assoc 57:348–368CrossRef
Metadata
Title
Adverse effects of antipsychotic drugs: survey of doctors’ versus patients’ perspective
Authors
Michela Nosè
Maria Angela Mazzi
Eleonora Esposito
Marco Bianchini
Paola Petrosemolo
Giovanni Ostuzzi
Michele Tansella
Corrado Barbui
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Social Psychiatry and Psychiatric Epidemiology / Issue 1/2012
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-010-0320-1

Other articles of this Issue 1/2012

Social Psychiatry and Psychiatric Epidemiology 1/2012 Go to the issue

Original Paper

Suicidal behavior among Muslim Arabs in Israel

Original Paper

Depressive symptoms among immigrants and ethnic minorities: a population based study in 23 European countries

Original Paper

Prevalence and correlates of psychotic symptoms among Asian males

Original Paper

Mental health symptoms associated with morbidity, not mortality, in an elderly community sample

Original Paper

Co-occurring risk behaviors among White, Black, and Hispanic US high school adolescents with suicide attempts requiring medical attention, 1999–2007: Implications for future prevention initiatives

Original Paper

The profile of suicide: changing or changeable?